药剂师在社区药房中实施基于种族的资格标准服务的经验
Joanna Hikaka1,2, Florence Tauvae Tuiletufuga1,2, Brendon McIntosh1
1Ngā Kaitiaki o Te Puna Rongoā o Aotearoa - The Māori Pharmacists' Association, Taupō 3330, Aotearoa, New Zealand.
The International journal of pharmacy practice
|March 2, 2026
概括
药剂师需要更好的培训和资源,以有效地实施基于种族的资格标准 (EBEC) 在社区药房. 加强支持对于公平的医疗保健提供和解决患者需求至关重要.
科学领域:
- 医疗保健服务研究 医疗服务研究
- 药房实践 在药房实践.
- 健康 公平 卫生 公平
背景情况:
- 药剂师通过解决系统性障碍,在公平的医疗保健中发挥关键作用.
- 基于种族的资格标准 (EBEC) 可以改善治疗机会,但社区药剂师对其实施的研究不足.
- 了解药剂师与EBEC的经验对于有效的医疗保健服务至关重要.
研究的目的:
- 探索社区药剂师对在实践中应用EBEC的看法.
- 评估未来教育和EBEC实施资源的感知有用性.
- 通过EBEC识别公平医疗保健提供障碍和促进者的障碍.
主要方法:
- 在新西兰的奥特罗亚州,对药剂师进行了一项描述性的横截面调查.
- 数据是使用试点在线调查匿名收集的.
- 使用描述性统计数据分析了定量数据,主题分析了定性数据.
主要成果:
- 218名药剂师参加了这次考试,其中最舒服的是使用EBEC,但有一半希望得到更好的支持.
- 药剂师报告说,与患者讨论种族的经验有限,并寻求提高沟通技巧.
- 关键的资源需求包括EBEC的证据,种族定义和沟通策略.
结论:
- 在社区药房有效实施EBEC需要适当的培训和资源.
- 药剂师需要加强支持,以导航有关种族和资格标准的讨论.
- 有针对性的教育和资源对于药剂师来说至关重要,以使用EBEC提供公平的护理.
更多相关视频
相关概念视频
Analysis of Population Pharmacokinetic Data
993
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
993
Drug Dosing: Geriatric Patients
392
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
392
Pharmacogenetics and Pharmacogenomics: Overview
248
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
248
Principles of Pharmacogenetics: Types of Genetic Variants
137
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
137
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
157
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
157
Pharmacogenetics of Drug Metabolism: Overview
191
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
191


